Sami Corwin, an analyst from William Blair, has initiated a new Buy rating on Crispr Therapeutics AG (CRSP).
Sami Corwin has given his Buy rating due to a combination of factors including the promising clinical data and commercial progress of Crispr Therapeutics AG. The company’s collaboration with Vertex Pharmaceuticals has resulted in the activation of over 65 authorized treatment centers globally, with more than 90 patients initiating cell collection, indicating a strong commercial launch of Casgevy for sickle cell disease and transfusion-dependent β-thalassemia.
Additionally, Crispr Therapeutics reported encouraging top-line data from its CTX310 program, which demonstrated significant reductions in ANGPTL3, triglycerides, and LDL levels in patients. The absence of clinically significant changes in liver enzymes and other safety markers further supports the potential of their gene-editing programs. These developments, along with anticipated updates on other clinical trials, underpin the positive outlook and Buy rating from Sami Corwin.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $105.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.